TB Alliance

TB Alliance announces European Commission authorisation of new treatment for highly drug-resistant TB

Pretomanid, developed by the non-profit TB Alliance, has received EU marketing authorisation in combination regimen with bedaquiline and linezolid in adults with XDR-TB or treatment-intolerant/non-responsive MDR-TB.

Read More →

Mylan secures DCGI approval in India for pretomanid, a treatment for highly drug-resistant forms of TB

Pretomanid is only the third new anti-tuberculosis (TB) drug developed specifically for drug-resistant forms of the disease to be approved in more than 40 years

Approval comes as a result of Mylan’s global collaboration with non-profit drug development partner TB Alliance

Read More →

InveniAI announces strategic partnership with TB Alliance to advance the development of transformative therapies for TB

Guilford, Conn., June 2, 2020 - InveniAI® LLC, a global leader pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across drug discovery and development, is pleased to announce a strategic partnership with TB Alliance, a non-profit organization dedicated to the discovery, development, and delivery of better, faster-acting and affordable tuberculosis (TB) drugs. TB Alliance will make use of InveniAI’s AI and machine learning platform, AlphaMeld®, to identify and accelerate transformative therapies for the management, treatment, and cure of TB, which remains the world’s top infectious disease killer.

Read More →

TB Alliance announces partnership with Hongqi Pharma to commercialize new therapy for highly drug-resistant forms of TB in China

NEW YORK (January 16, 2020)—Non-profit drug developer TB Alliance has granted Shenyang Hongqi Pharmaceuticals Co., Ltd. (“Hongqi Pharma”), a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, stock code: 600196.SH; 02196.HK) a license to market the anti-TB medicine pretomanid as part of the three-drug “BPaL” regimen. Hongqi has agreed to commercialize the anti-tuberculosis (TB) medicine in the People’s Republic of China.

Read More →

TB Alliance responds to questions raised by activists in relation to pretomanid

MSF, TAG and TB CAB raised a number of outstanding medical and research questions regarding pretomanid and the regimen BPaL.

Read More →

TB Alliance and Macleods announce commercial partnership for new therapy for highly drug-resistant TB

NEW YORK and MUMBAI (October 28, 2019)—Non-profit drug developer TB Alliance has granted Macleods Pharmaceuticals Limited a non-exclusive license to manufacture the anti-TB drug pretomanid as part of the three-drug “BPaL” regimen. Pending regulatory approvals, Macleods has agreed to commercialize the anti-tuberculosis (TB) medicine in approximately 140 countries and territories.

Read More →

FDA approves pretomanid for highly drug-resistant forms of TB

Pretomanid receives FDA approval in combination regimen with bedaquiline and linezolid for people with XDR-TB or treatment-intolerant/non-responsive MDR-TB.

Read More →

TB community urges global leaders to “Walk the Talk” on investing in TB research

On July 28th in South Africa, more than 100 members of the TB research community marched under the Louder than TB banner in the Walk the Talk event to raise awareness for TB and TB research.

Read More →

New milestone for children with TB reached as one million treatments of child-friendly medicines are ordered

SYDNEY (June 18, 2019)—TB Alliance today announced that one million treatment courses of child-friendly tuberculosis (TB) medicines have been ordered by 93 countries in the three years since introduction of the products.1 The new medicines, which were first introduced nationally in Kenya in September 2016, are easier for caregivers to administer and for children to take. The announcement took place at the first International Global Health Security Conference in Sydney.

Read More →

FDA Antimicrobial Drugs Advisory Committee recommends approval of pretomanid

Investigational drug pretomanid is under regulatory review by FDA for treatment of XDR-TB and treatment-intolerant or non-responsive MDR-TB as part of a new investigational regimen.

Read More →

Page 1 of 8 · Total posts: 10

1 2 Last→